Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches
- PMID: 9519339
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches
Abstract
It is well established that elevated circulating concentrations of cholesterol-rich, low-density lipoproteins (LDL) represent a major risk factor for the premature development of coronary artery disease. Only recently, however, has attention been drawn to the relationship between the qualitative features of plasma LDL particles and cardiovascular risk, particularly in view of the frequent occurrence of increased levels of dense, small LDL in coronary artery disease patients. Combined hyperlipidaemia, a frequent form of dyslipidaemia which is associated with premature atherosclerosis, is characterized by elevated plasma concentrations of both triglyceride-rich, very-low-density lipoproteins (VLDL) and LDL. In combined hyperlipidaemia patients, small, dense LDL (d 1.04-1.06 g.ml-1) predominate over the light (d 1.02-1.03 g.ml-1) and intermediate (d 1.03-1.04 g.ml-1) LDL subpopulations. Dense LDL are highly atherogenic as a result of their low binding affinity for the LDL receptor, their prolonged plasma half-life and low resistance to oxidative stress. Biological modification of dense LDL is potentiated as a result of retention in the arterial intima upon binding to extracellular matrix components and exposure to oxidative stress, leading to uptake by macrophages with subsequent foam cell formation. Such cholesterol-loaded, macrophage foam cells are active secretory cells, and exert multiple proinflammatory, proatherogenic and prothrombogenic effects during the initiation and progression of atherosclerotic plaques. Indeed, the secretory products of foam cells play a key role in the fragilization of lipid-rich plaques, leading ultimately to plaque rupture and the associated thrombotic complications. As the pharmacological modulation of dense LDL levels is of special interest, representing a new therapeutic approach in the treatment of atherogenic dyslipidaemia, we probed the biological mechanisms which underlie formation of dense LDL particles in combined hyperlipidaemia patients with a fibrate derivate, fenofibrate. Drug treatment (micronized fenofibrate, 200 mg.day-1 for 8 weeks) induced significant reductions in the plasma concentrations of VLDL (-37%; P < 0.005), and of dense LDL (-21.5%; P < 0.05), with simultaneous increase in HDL-cholesterol (+19%; P < 0.0001). An endogenous assay of cholesteryl ester transfer from cardioprotective HDL to atherogenic, apolipoprotein B-containing lipoproteins (VLDL and LDL) revealed marked reduction (-38%) in cholesterol ester transfer from HDL to VLDL upon fenofibrate treatment, whereas no modification in the low rate of cholesteryl ester transfer between HDL and LDL was detected. Simultaneously, however, the LDL profile in combined hyperlipidaemia patients, which is characterized by a predominance of small, dense LDL, was shifted towards the LDL subpopulation of intermediate density and larger size. Particles of the intermediate LDL subclass are avidly bound and degraded by the cellular LDL receptor which represents the major, non-atherogenic pathway for catabolism of LDL-cholesterol. Our findings indicate that the overall mechanism of the fenofibrate-induced modulation of the atherogenic dense LDL profile in combined hyperlipidaemia involves reduction in cholesteryl ester transfer from HDL to VLDL, together with normalization of the intravascular transformation of hepatic VLDL to receptor-active LDL of intermediate density.
Similar articles
-
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.Atherosclerosis. 2002 Aug;163(2):287-96. doi: 10.1016/s0021-9150(02)00037-0. Atherosclerosis. 2002. PMID: 12052475 Clinical Trial.
-
[Role of anomalies of low density lipoproteins (LDL) in atherogenicity].Bull Acad Natl Med. 2001;185(1):35-7; discussion 38-9. Bull Acad Natl Med. 2001. PMID: 11474567 French.
-
The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.Diabetes Metab. 1999 Sep;25(3):199-211. Diabetes Metab. 1999. PMID: 10499189 Review.
-
Overview of fenofibrate.Eur Heart J. 1998 Feb;19 Suppl A:A62-5. Eur Heart J. 1998. PMID: 9519345 Review.
-
Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):763-72. doi: 10.1161/01.atv.16.6.763. Arterioscler Thromb Vasc Biol. 1996. PMID: 8640404
Cited by
-
LDL binding to cell receptors and extracellular matrix is proatherogenic in obesity but improves after bariatric surgery.J Lipid Res. 2023 Nov;64(11):100451. doi: 10.1016/j.jlr.2023.100451. Epub 2023 Sep 28. J Lipid Res. 2023. PMID: 37777014 Free PMC article.
-
Chemistory of Fibrates.Curr Chem Biol. 2007 Sep;1(3):311-316. doi: 10.2174/187231307781662198. Curr Chem Biol. 2007. PMID: 34485047 Free PMC article.
-
Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population.J Int Med Res. 2021 Jul;49(7):3000605211019263. doi: 10.1177/03000605211019263. J Int Med Res. 2021. PMID: 34275374 Free PMC article.
-
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7. Curr Diab Rep. 2021. PMID: 33742318 Free PMC article. Review.
-
Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality.Diabetologia. 2020 Feb;63(2):253-260. doi: 10.1007/s00125-019-05024-3. Epub 2019 Nov 11. Diabetologia. 2020. PMID: 31713012 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials